ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 11/21/23

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference on November 30, 2023, at 1:00 p.m. ET. A webcast of the presentation may be accessed on the Events and Presen...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal year ended September 30, 2023. Webcast and Conference Call and Details Investors may acce...

- Plozasiran achieved mean max reductions of up to 90% in APOC3 and 87% in triglycerides in patients with severe hypertriglyceridemia - In patients with mixed dyslipidemia, mean max reduction in APOC3 was up to 89% leading to robust and durable reductions in multiple atherogenic lipoproteins ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on November 16, 2023, at 13:30 GMT. A webcast of the presentation may be accessed on the Events and Presentations pa...

- Company will also host a virtual analyst and investor event on November 13, 2023 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zo...

2023-10-31 10:31:16 ET More on Arrowhead Pharma Arrowhead Pharmaceuticals: A High-Risk, High-Reward Bet Arrowhead Remains Well-Positioned For RNAi-Based Therapeutic Breakthroughs Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Call Transcript Ionis la...

2023-10-29 23:51:13 ET Summary Novartis recently completed the spin-off of Sandoz which improved its growth and margin profile. The biopharma business is in good shape with a decent collection of high-growth products and pipeline opportunities. The recent share price correctio...

2023-10-26 01:47:29 ET Summary Arrowhead Pharmaceuticals presents a complex investment opportunity with substantial risks and significant growth prospects. Despite revenue volatility and escalating operational costs, the company has a strong cash reserve and partnerships for finan...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2023 Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting – October 4-6, 2023 Date: October 5, 2023 Type: Poster Presentat...

2023-09-26 15:08:59 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Novartis and Ionis in pact for new cardiovascular therapy AstraZeneca-Ionis deal for eplontersen expands to Latin America S...